title: [Efficiency perindopril at patients with arterial hypertension   and obesity].
abstract: We gave perindopril (10 mg/day) for 24 weeks to 30 patients with arterial hypertension and obesity and proved its ability to effectively lower arterial pressure, exert cardio-, angio-, and nephro-protection, improve parameters of lipid, carbohydrate and purine metabolisms in these patients. Moreover perindopril in these patients diminished manifestations of insulin resistance, hyperleptinemia, and inflammation; it also exerted pronounced positive effect on anthropometric parameters and percent of fat deposits. Basing on the aggregate of clinical and pharmacodynamics effects perindopril can be considered the drug of choice for treatment  of  arterial hypertension at the background of obesity.
authors: S V
authors: SV
authors: Nedogoda
authors: A A
authors: AA
authors: Lediaeva
authors: E V
authors: EV
authors: Chumachok
authors: V V
authors: VV
authors: Tsoma
authors: G G
authors: GG
authors: Mazina
authors: A S
authors: AS
authors: Salasiuk
mesh_terms: D000273:Adipose Tissue / Q000187:drug effects / Q000378:metabolism; D000328:Adult; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D001794:Blood Pressure / Q000187:drug effects*; D015992:Body Mass Index; D016903:Drug Monitoring / Q000379:methods*; D004656:Enalapril / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D005260:Female; D006334:Heart Function Tests; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D007333:Insulin Resistance; D007677:Kidney Function Tests; D008297:Male; D008660:Metabolism / Q000187:drug effects; D008875:Middle Aged; D009765:Obesity / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D020913:Perindopril / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D020011:Protective Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D013810:Therapeutic Equivalency; D016896:Treatment Outcome
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D020011:Protective Agents; D004656:Enalapril; D020913:Perindopril